AGTR1 and lymphangioleiomyomatosis: In conclusion, consistent with previous data showing the importance of AGTR1 (20, 21) in LAM and AML (22), this study demonstrates both in vitro and in vivo and offers the scientific rationale to target AGTR1 in LAM and in TSC.